Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

SHE:301211 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	417.58	447.66	543.14	1,694	1,858	1,860
Trading Asset Securities	1,122	1,107	1,094	129.4	103.98	-
Cash & Short-Term Investments	1,540	1,555	1,637	1,824	1,962	1,860
Cash Growth	-1.93%	-5.00%	-10.26%	-7.05%	5.50%	438.28%
Accounts Receivable	76.14	91.47	75.53	75.08	127.47	161.05
Other Receivables	6.02	5.95	9.26	2.66	1.35	3.09
Receivables	82.16	97.42	84.79	77.74	128.82	164.14
Inventory	139.34	122.68	137.85	173.8	114.7	89.5
Other Current Assets	23.81	16.57	15.28	23.59	21.21	15.67
Total Current Assets	1,785	1,792	1,875	2,099	2,227	2,129
Property, Plant & Equipment	524.46	525.89	527.75	361.99	184.8	131.7
Long-Term Investments	10.38	10.38	9.64	-	-	-
Other Intangible Assets	67.32	66.83	68.94	71.07	73.27	66.67
Long-Term Deferred Tax Assets	2.36	2.36	2.05	2.19	2.39	1.52
Long-Term Deferred Charges	2.53	4.38	1.05	1.33	-	-
Other Long-Term Assets	0.18	0.43	4.61	11.03	11.47	1.24
Total Assets	2,392	2,402	2,489	2,547	2,499	2,330

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	59.18	72.27	116.04	117.71	82.62	36.13
Accrued Expenses	11.67	17.09	14.99	12.92	11.64	8.86
Current Portion of Leases	-	1.13	1.59	1.51	0.97	-
Current Income Taxes Payable	4.16	1.13	3.13	14.27	18.14	12.84
Current Unearned Revenue	14.24	9.15	11.87	15.01	69.72	6.34
Other Current Liabilities	10.76	13.78	16.76	13.73	25.82	38.84
Total Current Liabilities	101.13	114.55	164.38	175.14	208.91	103.01
Long-Term Leases	0.8	2.01	3.62	5.15	6.43	-
Long-Term Unearned Revenue	1.95	1.96	2.04	2.1	0.22	0.28
Long-Term Deferred Tax Liabilities	10.13	10.13	8.92	7.49	6.7	4.24
Total Liabilities	114	128.65	178.97	189.89	222.26	107.53

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	417.6	417.6	288	288	240	240
Additional Paid-In Capital	1,627	1,627	1,757	1,757	1,805	1,805
Retained Earnings	233.47	228.39	265.48	312.17	232.06	178.26
Comprehensive Income & Other	0.33	0.33	-0.3	-	-	-
Total Common Equity	2,278	2,273	2,310	2,357	2,277	2,223
Shareholders' Equity	2,278	2,273	2,310	2,357	2,277	2,223
Total Liabilities & Equity	2,392	2,402	2,489	2,547	2,499	2,330

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	1.92	3.13	5.22	6.66	7.4	-
Net Cash (Debt)	1,538	1,552	1,631	1,817	1,955	1,860
Net Cash Growth	-1.84%	-4.88%	-10.22%	-7.04%	5.10%	438.28%
Net Cash Per Share	3.92	3.56	3.92	4.34	4.71	5.97
Filing Date Shares Outstanding	400.13	417.6	417.6	417.6	417.6	417.6
Total Common Shares Outstanding	400.13	417.6	417.6	417.6	417.6	417.6
Working Capital	1,684	1,677	1,710	1,924	2,018	2,026
Book Value Per Share	5.69	5.44	5.53	5.64	5.45	5.32
Tangible Book Value	2,211	2,206	2,241	2,286	2,203	2,156
Tangible Book Value Per Share	5.53	5.28	5.37	5.47	5.28	5.16
Buildings	-	286.89	257.27	114.69	107.54	103.36
Machinery	-	460.78	405.47	185.73	180.96	173.8
Construction In Progress	-	8.2	53.5	228.77	51.56	2.17

Data Source: S&P Global Market Intelligence Last updated: Aug 24, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 9, 2026

Data Sources Report a data error